Sylvia, Garrett, Leila —
I want to lay out our preparation plan for the Appeals conference now scheduled for **February 28, 2024**, at the IRS Appeals Office in Manhattan. The assigned Appeals Officer is **Noreen Castañeda**, who came on in January. As you all know, this is PPC's opportunity to present our defense of the **$380.4 million** in proposed adjustments across TY 2017–2020 (NOPA issued October 12, 2023; Formal Protest filed December 22, 2023). We need to be airtight — on substance and logistics both. I'm setting out assignments, deadlines, and key themes below.
---
**ATTENDEES**
Confirmed attendees for February 28:
- **Calderwood & Harkness:** Leonard Cross, Sylvia Hartwell, Garrett Simmons - **PPC:** Marcus Whitfield (VP, Global Tax), Deborah Staines (General Counsel) - **Whitmore Valuation Group:** Dr. Helena Vasquez (Managing Director / Lead Economist) - **IRS:** Appeals Officer Noreen Castañeda (and possibly an IRS counsel representative)
Leila, you will not attend the conference itself but will be on standby at the Philadelphia office for real-time research support and available by phone throughout the day.
Garrett — please finalize and circulate the attendee list document by end of week.
---
**PRESENTATION — GARRETT**
Garrett, you are responsible for finalizing the Northgate Services Inc. presentation for the conference. The presentation should be organized by issue as follows:
1. **Case Overview and Factual Background** — PPC's IP structure, the CSA effective July 1, 2012, the PCT payment of $312M, PBI's role as IP holder and non-Americas principal.
2. **CSA Cost-Sharing Ratios** — PPC's positions (38.2%–42.7% across 2017–2020) vs. IRS's proposed increases (48.2%–53.7%), with the reasonably anticipated benefits methodology under Treas. Reg. § 1.482-7. Total CSA adjustments at issue: **$235.01M**.
3. **Legacy IP Royalty Rate** — PPC's 4.5% rate vs. IRS's proposed 11.0%. Whitmore's CUT analysis: 14 comparable pharmaceutical license agreements, IQR of 3.1%–6.8%, median 4.4%. Total royalty adjustments at issue: **$188.04M**. Correlative offset of **$42.65M**.
4. **PCT Valuation** — Whitmore's DCF/income method using 9.8% WACC supports $312M within arm's-length range of $278M–$361M; IRS used 7.2% WACC to arrive at $852M.
5. **PBI Economic Substance / DEMPE Functions** — 185 employees (up from 52 in 2012), 42 board meetings in Dublin (2017–2020), €47.2M cumulative regulatory spend, ~18,000 sq ft office at Sandyford Business Park, independent pricing decisions across 68 country markets, local banking with Glenmore Bank Ireland plc.
6. **Penalty Protection** — Contemporaneous documentation prepared by Crestfield & Associates under IRC § 6662(e)(3)(B); reasonable cause defense.
7. **Proposed Resolution Framework** — Our settlement posture (more on this below).
Please coordinate directly with **Dr. Vasquez** on her slides covering the economic analyses (CUT, CPM/TNMM, DCF). I know you sent her the updated data on February 10 — make sure her slides reflect those latest numbers.
**Deadline: Draft presentation to me and Sylvia by February 21** — that gives us a full week before the conference.
---
**DOCUMENT BINDERS — LEILA**
Leila, you are responsible for assembling the physical document binders for the conference. We need one per attendee — at least **6 copies plus 2 extras** for the IRS side. Each binder should be tabbed and indexed per the Table of Contents we've already prepared:
- **Tab 1:** Formal Protest (filed December 22, 2023) - **Tab 2:** Protest Exhibit A — PPC corporate structure chart (PPC → PHL → PBI → PMI) - **Tab 3:** Protest Exhibit B — Summary of CSA terms (effective date July 1, 2012, PCT $312M, cost-sharing percentages 2017–2020) - **Tab 4:** Protest Exhibit C — Summary of economic analyses (CUT, CPM/TNMM, DCF) - **Tab 5:** Protest Exhibit D — PBI economic substance evidence - **Tab 6:** Protest Exhibit E — Penalty protection documentation - **Tab 7:** Whitmore's CUT analysis report (14 comparables, IQR 3.1%–6.8%) - **Tab 8:** Whitmore's CPM/TNMM analysis (22 comparable companies) - **Tab 9:** Whitmore's PCT valuation / DCF report ($278M–$361M range) - **Tab 10:** Whitmore's WACC/Discount rate analysis (9.8% vs. IRS 7.2%) - **Tab 11:** Rebuttal of IRS Economist Dr. Washburne's analysis (prepared by Dr. Vasquez and Dr. Chakrabarti, January 2024) - **Tab 12:** Functional analysis of PBI (updated March 2023 version) - **Tab 13:** PBI personnel interview summaries (12 key employees) - **Tab 14:** PBI board minutes analysis (42 meetings) - **Tab 15:** DEMPE functions matrix - **Tab 16:** Key legal authorities (IRC § 482, Treas. Reg. §§ 1.482-4, 1.482-7, § 1.482-1(d); case law — *Altera*, *Harborview Corporation*, *Amazon*) - **Tab 17:** OECD Transfer Pricing Guidelines excerpts (Chapter VI, Chapter VIII) - **Tab 18:** Settlement range analysis (sensitivity analysis workbook, printed summary page)
**Deadline: Binders assembled and ready for my review by February 26** — two days before the conference.
Please confirm printing and binding logistics with our Philadelphia office support staff right away so we don't run into any last-minute bottlenecks.
---
**WITNESS AND SPEAKER PREPARATION**
Here is how I see the speaking roles at the conference:
- **Cross:** I will handle the opening presentation and lead the legal arguments — IRC § 482, arm's-length standard, best method rule, CSA defense, royalty rate defense, penalty protection, and the closing/settlement discussion.
- **Sylvia:** You'll address any procedural or engagement-level questions and manage the flow of Q&A. If Appeals Officer Castañeda raises settlement authority, you and I will handle that together.
- **Garrett:** You'll support me with factual and economic backup during the presentation, manage handouts and binder references in real time, and take detailed notes for our post-conference summary.
- **Dr. Vasquez:** She will present the economic analyses — CUT analysis, CPM/TNMM results, PCT DCF valuation, and rebuttal of Dr. Washburne's methodology. Garrett, the witness preparation memo for Dr. Vasquez is your responsibility — **due February 22**. Walk her through the anticipated questions on comparable selection methodology, discount rate assumptions, and specifically why the IRS's CUT choices and 7.2% WACC are flawed.
- **Marcus Whitfield:** Marcus may be called upon to speak to PPC's business rationale, PBI's operational role, and the company's transfer pricing compliance process. I am finalizing his witness prep memo — **target completion February 20**. Key messaging: PBI is a substantive entity making real commercial decisions, not a shell. PPC's transfer pricing positions were established in good faith based on arm's-length analysis and contemporaneous documentation.
- **Deborah Staines:** Deborah will attend in her capacity as General Counsel. She is not expected to present but should be prepared to address any governance or corporate-structure questions that come up.
---
**KEY ARGUMENTS — THEMES TO DRIVE HOME**
A brief reminder of the core themes we need to hammer at the conference:
1. PPC's **4.5% royalty rate** sits squarely within the arm's-length range (IQR 3.1%–6.8%, median 4.4%) based on 14 comparable uncontrolled transactions. The IRS's 11.0% rate is based on cherry-picked, non-comparable agreements.
2. PBI's **cost-sharing percentages (38.2%–42.7%)** accurately reflect reasonably anticipated benefits. The IRS's proposed increases of 8–12 percentage points are unsupported by the actual revenue data and projections.
3. The **$312M PCT payment** falls within the $278M–$361M arm's-length range using a properly risk-adjusted WACC of 9.8%. The IRS's 7.2% discount rate understates the risk inherent in pharmaceutical IP development.
4. **PBI has robust economic substance** — this is not a brass-plate entity. 185 employees, 42 board meetings, €47.2M in regulatory submissions, independent pricing across 68 markets. The DEMPE analysis clearly shows PBI controls key exploitation functions for non-Americas territories.
5. PPC maintained **contemporaneous documentation** for all four years, prepared by Crestfield & Associates. The § 6662(e) penalty is unsupportable — both on reasonable cause and documentation grounds.
---
**SETTLEMENT POSTURE**
As established in our December 10, 2023 memo, our target resolution is **10–15% of the $380.4M proposed adjustment**, with a **hard ceiling of 20%**. We should not initiate settlement discussion — let Appeals Officer Castañeda raise it. But if she does, we are prepared. Keep the sensitivity analysis workbook (modeled at 5%, 10%, 15%, 20%, 25% of the proposed adjustment) at hand for quick reference.
---
**LOGISTICS**
- The conference is at the **IRS Appeals Office, Manhattan** — I will confirm the exact address and room assignment shortly. - Plan to arrive by **8:30 AM** for a **9:00 AM** start. - Travel: I will be coming from Philadelphia with Garrett and Dr. Vasquez. Sylvia, you'll come from our New York office. Marcus and Deborah are traveling from PPC headquarters in Princeton Junction. - **Leila** — please arrange a conference room at our New York office (**600 Lexington Avenue**) for a **pre-conference team huddle at 7:30 AM** on February 28. Also, please make sure you are reachable at the Philadelphia office throughout the day for any real-time research needs.
---
**DEADLINES SUMMARY**
| Date
---
I want to thank each of you for the extraordinary work you've put in over the past 20 months — 47 IDRs, the NOPA response, the Protest. This conference is PPC's best opportunity to demonstrate the strength of its positions and drive toward a favorable resolution. Let's make sure we walk in fully prepared.
Please flag any questions or conflicts with the schedule by end of day today.
Best, Len
---
**Leonard Cross** Partner, Tax Department Calderwood & Harkness LLP 1735 Market Street, Suite 3100 Philadelphia, PA 19103 Direct: (215) 555-8214 lcross@calderwoodharkness.com
*Matter 1018-00009 — Penterra Pharmaceuticals Corp.*
---
*CONFIDENTIALITY NOTICE: This email and any attachments are attorney-client privileged and attorney work product. They are intended solely for the use of the individual(s) to whom they are addressed. If you are not the intended recipient, please notify the sender immediately and delete this message. Any unauthorized review, use, disclosure, or distribution is strictly prohibited.*